<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7605074</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6087</journal-id>
<journal-id journal-id-type="nlm-ta">Neuroscience</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuroscience</journal-id>
<journal-title-group>
<journal-title>Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0306-4522</issn>
<issn pub-type="epub">1873-7544</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26577932</article-id>
<article-id pub-id-type="pmc">4824539</article-id>
<article-id pub-id-type="doi">10.1016/j.neuroscience.2015.11.010</article-id>
<article-id pub-id-type="manuscript">NIHMS742578</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The serotonin system in autism spectrum disorder: from biomarker to animal models</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Muller</surname>
<given-names>Christopher L.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<email>christopher.l.muller@vanderbilt.edu</email>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Anacker</surname>
<given-names>Allison M.J.</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<email>aanacke@nyspi.columbia.edu</email>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Veenstra-VanderWeele</surname>
<given-names>Jeremy</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
<email>veenstr@nyspi.columbia.edu</email>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Vanderbilt Brain Institute, Vanderbilt University, 465 21<sup>st</sup> Ave S, Nashville, TN, 37232, USA</aff>
<aff id="A2"><label>b</label>Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Mail Unit 78, New York, NY, 10032, USA</aff>
<aff id="A3"><label>c</label>Center for Autism and the Developing Brain, New York Presbyterian Hospital, 21 Bloomingdale Road, White Plains, NY, 10605, USA</aff>
<author-notes>
<corresp id="FN1">Corresponding Author: Jeremy Veenstra-VanderWeele, 1051 Riverside Drive, Mail Unit 78, New York, NY, 10025, Office 646-774-5251, <email>veenstr@nyspi.columbia.edu</email></corresp>
<fn fn-type="conflict" id="FN3">
<p><bold>Biomedical conflicts of interest:</bold> Dr. Veenstra-VanderWeele has consulted with Roche Pharmaceuticals, Novartis, and SynapDx and has had research funding from Roche Pharmaceuticals, Novartis, SynapDx, Seaside Therapeutics, Forest, and Sunovion. He receives an honorarium for editorial work from Springer and John Wiley and Sons.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>15</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<day>3</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>03</day>
<month>5</month>
<year>2017</year>
</pub-date>
<volume>321</volume>
<fpage>24</fpage>
<lpage>41</lpage>
<!--elocation-id from pubmed: 10.1016/j.neuroscience.2015.11.010-->
<abstract>
<p id="P2">Elevated whole blood serotonin, or hyperserotonemia, was the first biomarker identified in autism spectrum disorder (ASD) and is present in more than 25% of affected children. The serotonin system is a logical candidate for involvement in ASD due to its pleiotropic role across multiple brain systems both dynamically and across development. Tantalizing clues connect this peripheral biomarker with changes in brain and behavior in ASD, but the contribution of the serotonin system to ASD pathophysiology remains incompletely understood. Studies of whole blood serotonin levels in ASD and in a large founder population indicate greater heritability than for the disorder itself and suggest an association with recurrence risk. Emerging data from both neuroimaging and postmortem samples also indicate changes in the brain serotonin system in ASD. Genetic linkage and association studies of both whole blood serotonin levels and of ASD risk point to the chromosomal region containing the serotonin transporter (SERT) gene in males but not in females. In ASD families with evidence of linkage to this region, multiple rare SERT amino acid variants lead to a convergent increase in serotonin uptake in cell models. A knock-in mouse model of one of these variants, SERT Gly56Ala, recapitulates the hyperserotonemia biomarker and shows increased brain serotonin clearance, increased serotonin receptor sensitivity, and altered social, communication, and repetitive behaviors. Data from other rodent models also suggest an important role for the serotonin system in social behavior, in cognitive flexibility, and in sensory development. Recent work indicates that reciprocal interactions between serotonin and other systems, such as oxytocin, may be particularly important for social behavior. Collectively, these data point to the serotonin system as a prime candidate for treatment development in a subgroup of children defined by a robust, heritable biomarker.</p>
</abstract>
<kwd-group>
<kwd>Genetic</kwd>
<kwd>monoamine</kwd>
<kwd>reuptake</kwd>
<kwd>platelet</kwd>
<kwd>neurodevelopment</kwd>
<kwd>multisensory</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>